ADAPY
Adaptimmune Therapeutics PLCCompany with tickers: ADAPY
CIK
1621227
Shares Outstanding
1,590,309,546
Website
https://www.adaptimmune.com
Investor Relations
https://www.adaptimmune.com/investors-and-media
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2025-09-02 | Gavin Wood | Chief Financial Officer | 16,000 | 2025-09-02 | Rowan Dartington |
| 2025-08-29 | William Bertrand | Chief Operating Officer | 34,500 | 2025-08-28 | ETrade by Morgan Stanley |
| 2025-08-15 | New Enterprise Associates, 16 LP | Affiliate | 3,250,000 | 2025-08-15 | J.P. Morgan Securities LLC |
| 2025-08-15 | New Enterprise Associates, 14 LP | Affiliate | 13,829,778 | 2025-08-15 | J.P. Morgan Securities LLC |
| 2025-01-17 | Norry Elliot | Chief Medical Officer | 5,584 | 2025-01-17 | Maxim Group |
| 2025-01-17 | Rawcliffe Adrian | Chief Executive Officer | 30,601 | 2025-01-17 | Maxim Group |
| 2025-01-17 | Lunger John | Chief Patient Supply Officer | 5,584 | 2025-01-17 | Maxim Group |
| 2025-01-17 | Bertrand William C JR | Chief Operating Officer | 5,584 | 2025-01-17 | Maxim Group |
| 2025-01-15 | Piccina Cintia | Chief Commercial Officer | 12,991 | 2025-01-15 | Maxim Group |
| 2025-01-15 | Lunger John | Chief Patient Supply Officer | 9,739 | 2025-01-13 | Maxim Group |
| 2025-01-15 | Norry Elliot | Chief Medical Officer | 12,392 | 2025-01-13 | Maxim Group |
| 2025-01-15 | Rawcliffe Adrian | Chief Executive Officer | 30,473 | 2025-01-13 | MAXIM GROUP |
| 2025-01-15 | Bertrand William C JR | Chief Operating Officer | 9,739 | 2025-01-13 | Maxim Group |
Showing 1–13 of 13 filings